Pharma M&A Forecast Sunny

Sunny with little chance of rain: Pharma M&A forecast

Pharma M&A Forecast Sunny

Pharma M&A activity is hot out the blocks for the first quarter, with activity in the Pharma, Medical & Biotech sector totaling $63.4 billion, higher than its 2013 counterpart at $14.2 billion.


On 9th April Mergermarket released its Global Q1 2014  Pharma, Medical & Biotech M&A Trend Report,  identifying large scale growth in the pharmaceutical sector, compared to last year. The first quarter, standing at $63.4 billion worth of deals, demonstrates a strong sector and a promising year ahead for Pharma M&A.


Alongside these statistics, the news of Sun Pharma’s acquisition of Ranbaxy, an Indian generics company for $4 billion adds weight to the sunny outlook. The deal will make it the 5th largest specialty generics company in the world and is expected to close by the end of 2014. If you would like to read more on the acquisition click here for Rachel’s post.


Putting the Mergermarket report together, with the size of the Sun and Ranbaxy deal, it can categorically be said that the forecast for future Pharma M&A deals is looking bright and sunny, with little rain in sight. It will be interesting to see how this year pans out and whether it continues to beat last years quarters.


Interested in Pharma M&A? If so why not learn more by signing up to the inaugural Pharma M&A Briefing on 10th June in London. Topics of discussion will vary from trends and forecasts, to the role that Biotech and Specialty Pharma play in M&A. Meet industry experts and gain a detailed insight into Pharma M&A. Click here to download a brochure for the event.


Pharma M&A Briefing Terrapinn